Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risankizumab - AbbVie/Boehringer Ingelheim

Drug Profile

Risankizumab - AbbVie/Boehringer Ingelheim

Alternative Names: ABBV 066; BI-655066; risankizumab-rzaa; SKYRIZI

Latest Information Update: 08 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer AbbVie; Boehringer Ingelheim
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crohn's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Plaque psoriasis; Psoriasis; Psoriatic arthritis
  • Registered Erythrodermic psoriasis; Generalised pustular psoriasis
  • Preregistration Ulcerative colitis
  • Phase III Palmoplantar pustulosis
  • Phase II Atopic dermatitis; Hidradenitis suppurativa
  • No development reported Unspecified
  • Discontinued Ankylosing spondylitis; Asthma

Most Recent Events

  • 31 May 2024 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of risankizumab for the treatment of Ulcerative colitis in the European Union
  • 30 Apr 2024 AbbVie completes a phase I bioavailability trial (In volunteers) in the US (IV, infusion) (NCT06054425)
  • 01 Apr 2024 Launched for Crohn's disease (In adolescents, In the elderly, In adults) in Canada (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top